好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comparing Clinicoradiographic Features of Biopsy-confirmed Primary CNS Vasculitis, Amyloid-beta-related Angiitis, and Cerebral Amyloid Angiopathy-related Inflammation: A Cohort Study
Autoimmune Neurology
S30 - Autoimmune Neurology: Clinical CNS Autoimmune and Inflammatory Disorders (4:42 PM-4:54 PM)
007

Distinguish clinicoradiographic features of primary CNS vasculitis (PCNSV), amyloid-beta-related angiitis (ABRA), and cerebral amyloid angiopathy-related inflammation (CAAri).

PCNSV, ABRA, and CAAri are rare inflammatory vasculopathies presenting with similar clinical manifestations, yet comparative studies distinguishing them are limited. In a biopsy-confirmed cohort of these entities, we compare relapse risk and clinicoradiographic features.

We retrospectively identified PCNSV, ABRA, and CAAri cases at Mass General Brigham. Patients with non-supportive pathology were excluded. CAA cases met Boston 2.0 criteria. Relapse required worsening symptoms and new MRI lesion(s). Time-to-event analyses used Fine-Gray models with death as competing risk, reported as subdistribution hazard ratios (sHR). Multivariate logistic regressions were used to distinguish predictors of PCNSV vs amyloid-related vasculopathy (ARV).

Thirty-five PCNSV, 17 ABRA, and 24 CAAri patients were followed for a mean of 7.0, 4.4, and 3.9 years, respectively. Relapse occurred in 17/35 PCNSV, 4/17 ABRA, and 3/24 CAAri; overall p=0.02. Competing-risk model referenced to PCNSV, CAAri had a significantly lower sHR (0.33, CI [0.12-0.90], p=0.03) and ABRA trended lower (sHR 0.42, p=0.095). Most PCNSV relapses occurred within 2 years; ARV relapses by 4 years. Across groups, frequencies differed for sulcal T2/FLAIR hyperintensity (p=0.003), cortical T2/FLAIR hyperintensity (p=0.002), cortical microhemorrhage/siderosis (p<0.001), and enlarged perivascular spaces (p<0.001). Multivariable, age-adjusted model (PCNSV vs ARV) showed high discrimination (AUC 0.94); younger age (odds ratio (OR) per year 0.88, p=0.01), subcortical microhemorrhage/siderosis (OR 66.8, CI 4.0-790], p=0.02), and absence of cortical microhemorrhage/siderosis (OR 0.008, CI [0.0-0.14], p=0.008) independently distinguished PCNSV from ARV. Microhemorrhages rapidly accrued within 6 weeks in 2 PCNSV, 2 ABRA, and 0 CAA-ri.

PCNSV relapses were more frequent and earlier than ARV. Younger age plus deep subcortical microhemorrhage/siderosis without cortical siderosis strongly favored PCNSV. Microhemorrhage accrual rate may help distinguish ABRA from CAA-ri. These findings aid in early therapeutic decision-making and monitoring.
Authors/Disclosures
James V. Nguyen, MD, MEd (Mass General Brigham)
PRESENTER
Dr. Nguyen has nothing to disclose.
Philippe-Antoine Bilodeau, MD (Massachusetts General Hospital) Dr. Bilodeau has nothing to disclose.
Joao Vitor Mahler, MD Dr. Mahler has received research support from The Sumaira Foundation.
Natalia Drosu Ms. Drosu has nothing to disclose.
Monique Anderson, MD, PhD (Mass General Hospital) Dr. Anderson has nothing to disclose.
Takahisa Mikami, MD (Massachusetts General Hospital) Dr. Mikami has nothing to disclose.
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School) Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.